Skip to main content
. Author manuscript; available in PMC: 2011 Apr 15.
Published in final edited form as: Cancer Res. 2010 Apr 13;70(8):3042–3051. doi: 10.1158/0008-5472.CAN-09-3761

Figure 2. Inhibition of integrin α4β1 function blocks lymphatic endothelial cell migration and lymphangiogenesis.

Figure 2

(A) Images and quantification of Lyve-1+ lymphatic vessels/field +/- SEM in VEGF-C saturated Matrigel from saline, anti-α4β1, anti-α5β1 or recombinant soluble VCAM-treated mice from these mice (n=10, *p<0.002). (B) Mean percent TUNEL+Lyve1+ vessels/field +/- SEM, *p < 0.0002, in Matrigel from A. (C) VEGF-C stimulated LEC migration in the presence of medium, anti-α4β1 or anti-α5β1 antibodies (cIgG) (*p < 0.01). (D) LEC in vitro “vessel” formation in the presence of anti-α4β1 or isotype matched control (anti-α5β1) antibodies; mean vessel branchpoints per 100× field +/-SEM (*p < 0.0001)